Use of methotrexate in inflammatory bowel disease in 2014: A User’s Guide

Table 3 Evidence for maintenance of remission of ulcerative colitis with methotrexate

Study	Dose (mean)	Route	No. of pts	Study design	Follow-upperiod (mo)	MTX responsemaintained?	Controlresponse	Significantlyeffective?
Kozarek	> 7.5 mg	sc	5	Open label	24	3/5 (60%)	N/A	N/A
Oren	12.5 mg	oral	32	Placebo-controlled	9	5/14 (36%)	10/18 (56%)	No
Mate-Jimenez	15 mg	oral	12	6-MP control	18	1/7 (14%)	7/11 (64%)	No
Paoluzi	12.5 mg	im	10	Open label	24	6/8 (75%)	N/A	N/A
Manosa	25 mg	Oral/	7	Retrospective	24	35%		N/A
		sc	33

MTX: Methotrexate.